Oncology Institute, INC 10-Q quarterly reports

The Oncology Institute reports significant revenue growth in Q3 2025, driven by dispensary and patient services, but faces continued net losses and a negative stockholders' equity, while taking steps to improve liquidity.

The Oncology Institute, Inc. reported increased revenue and improved operational efficiency in Q2 2025, alongside continued net losses and strategic capital raises.

The Oncology Institute's Q1 2025 results show a revenue increase driven by dispensary growth, alongside strategic debt management and a private placement to bolster liquidity.

The Oncology Institute's Q3 2024 results show a significant increase in dispensary revenue, offsetting a slight decrease in patient services revenue, while the company continues to expand its value-based oncology services.

The Oncology Institute's Q2 2024 results show a revenue increase driven by dispensary growth, offset by a decrease in patient services revenue, and a net loss of $15.5 million.

The Oncology Institute has filed an amendment to its Q1 2024 10-Q report to correct inadvertently omitted language in the certifications related to internal control over financial reporting.

The Oncology Institute's first quarter 2024 results show a significant increase in revenue, particularly in the dispensary and clinical trials segments, despite an overall net loss.